The estimated Net Worth of Jeremy P. Springhorn is at least $2.02 Million dollars as of 13 June 2024. Jeremy Springhorn owns over 2,231 units of Syros Pharmaceuticals stock worth over $38,247 and over the last 7 years he sold SYRS stock worth over $179,495. In addition, he makes $1,804,240 as Chief Business Officer at Syros Pharmaceuticals.
Jeremy has made over 9 trades of the Syros Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 2,231 units of SYRS stock worth $11,423 on 13 June 2024.
The largest trade he's ever made was buying 20,000 units of Syros Pharmaceuticals stock on 11 November 2019 worth over $99,600. On average, Jeremy trades about 2,049 units every 113 days since 2017. As of 13 June 2024 he still owns at least 23,756 units of Syros Pharmaceuticals stock.
You can see the complete history of Jeremy Springhorn stock trades at the bottom of the page.
Dr. Jeremy P. Springhorn Ph.D. serves as Chief Business Officer of the Company. Dr. Springhorn has served as our chief business officer since November 2017. Prior to joining us, Dr. Springhorn served as a partner in corporate development at Flagship Pioneering, a venture capital firm, from March 2015 to June 2017. Prior to that, he served in several progressively-responsible positions in research and corporate development at Alexion Pharmaceuticals, Inc. from 1992 to March 2015, most recently as Vice President, Corporate Development. Dr. Springhorn has served on the board of directors of uniQure NV since September 2017. Dr. Springhorn holds a B.A. in chemistry and biochemistry from Colby College and a Ph.D. in biochemistry and molecular biology from the Louisiana State University Medical Center.
As the Chief Business Officer of Syros Pharmaceuticals, the total compensation of Jeremy Springhorn at Syros Pharmaceuticals is $1,804,240. There are 2 executives at Syros Pharmaceuticals getting paid more, with Nancy Simonian having the highest compensation of $3,614,020.
Jeremy Springhorn is 57, he's been the Chief Business Officer of Syros Pharmaceuticals since 2017. There are 12 older and 6 younger executives at Syros Pharmaceuticals. The oldest executive at Syros Pharmaceuticals Inc. is Phillip Sharp, 75, who is the Independent Director.
Jeremy's mailing address filed with the SEC is C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju, and Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Syros Pharmaceuticals executives and other stock owners filed with the SEC include: